Zimmer Biomet (NYSE:ZBH) Announces Earnings Results

Zimmer Biomet (NYSE:ZBH) posted its quarterly earnings results on Tuesday. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04, FiscalAI reports. The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.31 earnings per share. Zimmer Biomet updated its FY 2026 guidance to 8.300-8.450 EPS.

Zimmer Biomet Trading Down 0.3%

NYSE:ZBH opened at $89.64 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. The firm has a market capitalization of $17.76 billion, a P/E ratio of 22.19, a P/E/G ratio of 2.29 and a beta of 0.62. Zimmer Biomet has a 12-month low of $84.59 and a 12-month high of $114.44. The business has a 50 day simple moving average of $90.02 and a 200 day simple moving average of $95.68.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date was Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of recent research reports. Sanford C. Bernstein upped their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a report on Friday, January 9th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Robert W. Baird reaffirmed a “neutral” rating and issued a $100.00 target price (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. UBS Group reduced their price target on Zimmer Biomet from $88.00 to $86.00 and set a “sell” rating on the stock in a research note on Wednesday, January 28th. Finally, The Goldman Sachs Group downgraded Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective for the company. in a research report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average target price of $106.10.

Institutional Trading of Zimmer Biomet

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Headlands Technologies LLC purchased a new stake in shares of Zimmer Biomet in the second quarter worth approximately $37,000. Mpwm Advisory Solutions LLC bought a new position in shares of Zimmer Biomet during the 3rd quarter valued at $65,000. Palisade Asset Management LLC acquired a new position in Zimmer Biomet during the third quarter worth $70,000. Caitong International Asset Management Co. Ltd boosted its position in Zimmer Biomet by 449.7% during the third quarter. Caitong International Asset Management Co. Ltd now owns 786 shares of the medical equipment provider’s stock worth $77,000 after purchasing an additional 643 shares during the period. Finally, Parallel Advisors LLC grew its stake in Zimmer Biomet by 43.4% in the 3rd quarter. Parallel Advisors LLC now owns 895 shares of the medical equipment provider’s stock valued at $88,000 after buying an additional 271 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.